Nektar Therapeutics (NKTR) Sees Early Weakness
- Stocks decline as interest rate uncertainty, earnings weigh
- ASML slides as Q1 sales fall short but firm still on track for 2025 revenue target
- United Airlines maintains forecast after Q1 results top Wall Street estimates
- US dollar weakens as market consolidates gains, but uptrend intact
- Abbott Laboratories (ABT) narrows 2024 earnings guidance, shares slip
- Hasbro (HAS) Announces Resignation of Cynthia Williams, President of Wizards of the Coast and Hasbro Gaming
- ICZOOM Group (IZM) Discloses Request to Withdraw Registration Statement on Form F-1
- Alaska Airlines flights resume after being grounded over aircraft system issue
- GE HealthCare (GEHC) Announces Resignation of Jan Makela, CEO of Imaging
- Barnes & Noble Education (BNED) Enters Definitive Agreement with Immersion (IMMR)
- After-hours movers: Alcoa rises; Equifax and Las Vegas Sands fall
- Midday movers: Travelers, JB Hunt fall; United Airlines rises
- After-hours movers: United Airlines, J.B. Hunt, and more
- Midday movers: Morgan Stanley, UnitedHealth rise; Tesla falls
- Morgan Stanley, UnitedHealth and Bank of America rise premarket; Tesla falls
Nektar Therapeutics (NKTR) Offers Additional Detail on Bristol-Myers Squibb Collaboration
September 27, 2016 7:50 AM EDTNektar Therapeutics (Nasdaq: NKTR) disclosed the following in a U.S. SEC filing on Tuesday:
Item 1.01 Entry into a Material Definitive Agreement.
On September 21, 2016, Nektar Therapeutics, a Delaware corporation (Nektar), entered into a Clinical Trial Collaboration Agreement (the Agreement) with Bristol-Myers Squibb Company, a Delaware corporation (BMS), pursuant to which Nektar and BMS will collaborate to conduct Phase 1/2 clinical trials evaluating Nektars IL-2-based CD122-biased agonist, known as NKTR-214, and BMSs human monoclonal antibody that binds PD-1, known as Nivolumab, as a potential combination treatment regimen in five tumor types... More
Bristol-Myers Squibb (BMY), Nektar Therapeutics (NKTR) to Evaluate Opdivo + NKTR-214 Combo
September 27, 2016 7:11 AM EDTBristol-Myers Squibb Company (NYSE: BMY) and Nektar Therapeutics (Nasdaq:... More